1.85
0.14 (8.19%)
| Penutupan Terdahulu | 1.71 |
| Buka | 1.81 |
| Jumlah Dagangan | 5,281,727 |
| Purata Dagangan (3B) | 1,297,959 |
| Modal Pasaran | 299,233,792 |
| Harga / Buku (P/B) | 0.900 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2025 - 18 Aug 2025 |
| EPS Cair (TTM) | -1.61 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.41% |
| Nisbah Semasa (MRQ) | 8.98 |
| Aliran Tunai Operasi (OCF TTM) | -199.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -108.00 M |
| Pulangan Atas Aset (ROA TTM) | -48.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Neumora Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.38 |
|
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 27.57% |
| % Dimiliki oleh Institusi | 60.19% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Softbank Group Corp. | 31 Mar 2025 | 6,541,190 |
| Mic Capital Management Uk Llp | 31 Mar 2025 | 4,460,700 |
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 31 Mar 2025 | 3,309,123 |
| Iconiq Capital, Llc | 31 Mar 2025 | 2,559,090 |
| Lunate Capital Ltd | 31 Mar 2025 | 2,124,143 |
| Lunate Holding Rsc Ltd | 31 Dec 2024 | 2,124,143 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 5.00 (Mizuho, 170.27%) | Beli |
| 5.00 (Needham, 170.27%) | Beli | |
| Median | 5.00 (170.27%) | |
| Purata | 5.00 (170.27%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 1.04 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 16 Jul 2025 | 5.00 (170.27%) | Beli | 1.40 |
| Needham | 13 May 2025 | 5.00 (170.27%) | Beli | 0.679 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 Jul 2025 | Pengumuman | Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 |
| 07 Jul 2025 | Pengumuman | Biotech’s Turning Point: 4 Stocks Poised to Ride the 2025 Wave |
| 12 May 2025 | Pengumuman | Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update |
| 28 Apr 2025 | Pengumuman | Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |